Volume : 12, Issue : 03, March – 2025
Title:
DESIGN AND DEVELOPMENT OF GLIPIZIDE FLOATING DRUG DELIVERY SYSTEM
Authors :
A. Teja *, V.Naveen Kumar , J.Divya, P.Naga Sindhu.
Abstract :
The floating drug delivery system (FDDS) is a novel way to increase the bioavailability of medications that are mostly absorbed in the stomach or upper gastrointestinal tract by extending the gastric residence time of dose forms. Based on the principles of buoyancy, this technique uses polymers or other materials to create a tablet or capsule that float in the stomach fluid, enabling a controlled and prolonged release of the medication. Because it can reduce side effects linked to traditional drug release systems and increase the therapeutic efficacy of medications with limited absorption windows, FDDS has drawn a lot of interest in the world of pharmaceutical research.
The several kinds of floating systems—such as effervescent, non-effervescent, and hydrodynamically balanced systems—as well as the design criteria, formulation methods, and variables affecting FDDS performance are the main topics of this review. Challenges such drug stability, potential patient compliance, and variations in stomach circumstances are also covered. Examined are the possible uses of FDDS in the treatment of illnesses such infections, heart problems, and stomach ulcers, indicating a bright future in drug delivery.
KEYWORDS: Floating drug delivery system (FDDS), Xanthan gum, Poly ethylene oxide, Sodium Carboxymethyl Cellulose, Carbopol, Glipizide, Preformulating Studies, Zero order kinetics, First order kinetics.
Cite This Article:
Please cite this article in press A. Teja et al., Design And Development Of Glipizide Floating Drug Delivery System.,Indo Am. J. P. Sci, 2025; 12 (03)
Number of Downloads : 10
References:
1.Chowdary KPR ,Srinivasa YR. Design and in vitro evaluation of mucoadhesive controlled release oral tablet of glipizide. Indian J Pharm. 2003;65:592-599.
2. Thombre AG, Denoto AR, Gibbes DC. Delivery of glipizide from asymmetric membrane capsules using
encapsulated excepients. J control release. 1999;60:333-341.
3. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs.2004;64:1339-1358.
4. Verma RK, Garg S. Development and evaluation of osmotically controlled oral delivery system of glipizide. Eur J Pharm Biopharm. 2004;57:513-525.
5. Baily CJ. Potential new treatments for type two diabetes. Tips. 2000;21:259-265.
6. Harlay CR. Glipizide GRTS has advantages over other second generation sulfonylurea. Clin Drug Invest. 2002;22:575-584.
7. Hesieh SH, Lin JD, Chang HY, Ho Ch, Liou MJ. Sustained release versus immediate release glipizide for the treatment of diabetes mellitus in Chinese patients: a randomized, double blind, double dummy, parallel group, 12 week clinical study. ClinTher. 2006;28:1318- 1326.
8. Muthu MS. Nanoparticles based on PLGA and its copolymer: an overview. Asian J Pharm. 2009;3:266-273.
9. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan University Journal. 2003;11:51-66.
10. Patel JK, Patel RP, Amin AF, Patel MM. Formulation and evaluation of mucoadhesive glipizide microspheres . AAPS Pharm Sci Tech. 2005;6:49-55.
11. Smidsrod O, Skjakbraek G. Alginate as immobilization matrix for cells. Trends Biotechnol.1990;8:71-78.
12. Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained release ophthalmic
delivery of ciprofloxacin hydrochloride. Drug Deliv. 2003;10:185–191.
12. Kubo W, Myazaki S, Attwood D. Oral sustained delivery of paracetamol from in situ- gelling gellan and sodium alginate formulations. Int J Pharm. 2003;258:55–64.
13. Dokka S, Rojanasakul Y. Novel non-endocytic delivery of antisense oligosaccharides. Adv Drug Deliv. 2000;44:35-42.
14. Gazori T, Khoshayand MR, Azizi E, Yazdizadeh P. Nomani A. Haririan I. Evaluation of alginate/chitosan nanoparticles as antisense delivery vector: Formulation, optimization and in vitro characterization. CarbohydPolym. 2009;77;599-606.